|
Sign In to gain access to subscriptions and/or personal tools.
|
New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis
H Michael Belmont
Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA
Marc Storch
Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA
Jill Buyon
Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA
Steven Abramson
Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA
The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University/Hospital for Joint Diseases Lupus Study Group Institutions were retrospectively reviewed. We identified 45 patients (38 female, seven male) who received a mean of 9 ± 1 (range 2-23) pulses of intravenous cyclophosphamide for diffuse proliferative glomerulone phritis (n = 28), focal proliferative glomerulonephritis (n = 7), membranous nephropathy (n = 5), mesangial nephropathy with sclerosis (n = 1) or nephritis without biopsy (n = 4). Forty-two of the 45 patients received cyclophosphamide after failing steroid therapy. During a follow-up period of 52 ± 3 months, nine patients progressed to end-stage renal disease (ESRD) with three additional patients experiencing a doubling of the creatinine and two patients persistent nephrotic range proteinuria. There were no deaths directly attributable to cyclophosphamide and no patients developed hemorrhagic cystitis or malignancy. Ten of 37 women had ceased menstruating prior to cyclophosphamide therapy. Treatment-associated amenorrhea occurred in only three patients all over 27 years of age. Intermittent intravenous cyclophosphamide therapy of lupus nephritis is well tolerated and usually effective in maintaining renal function in patients unresponsive to steroids although, in our experience, 20% of patients developed ESRD and a total of 14 of 45 (30%) patients had unsatisfactory outcomes.
Key Words: systemic lupus erythematosus • cyclophosphamide • nephritis
Lupus, Vol. 4, No. 2,
104-108 (1995)
DOI: 10.1177/096120339500400205
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Mak, A. A. C. Cheak, J. Y. S. Tan, H. C. Su, R. C. M. Ho, and C. S. Lau
Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression
Rheumatology,
August 1, 2009;
48(8):
944 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Illei, C. H. Yarboro, T. Kuroiwa, R. Schlimgen, H. A. Austin, J. F. Tisdale, P. Chitkara, T. Fleisher, J. H. Klippel, J. E. Balow, et al.
Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis
Rheumatology,
June 1, 2007;
46(6):
952 - 956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G E Katsifis and A G Tzioufas
Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide
Lupus,
September 1, 2004;
13(9):
673 - 678.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C C Mok, R W S Wong, and K N Lai
Treatment of severe proliferative lupus nephritis: the current state
Ann Rheum Dis,
September 1, 2003;
62(9):
799 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. John, K. Lietz, M. Schuster, Y. Naka, V. Rao, D. M. Mancini, E. A. Rose, C. R. Smith, M. C. Oz, N. M. Edwards, et al.
Immunologic sensitization in recipients of left ventricular assist devices
J. Thorac. Cardiovasc. Surg.,
March 1, 2003;
125(3):
578 - 591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. E. Katsifis, A. G. Tzioufas, P. G. Vlachoyiannopoulos, M. Voulgarelis, H. M. Moutsopoulos, and J. P. A. Ioannidis
Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus
Rheumatology,
July 1, 2002;
41(7):
780 - 786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al.
Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis
Ann Intern Med,
August 21, 2001;
135(4):
248 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Takada, G G Illei, and D T Boumpas
Cyclophosphamide for the treatment of systemic lupus erythematosus
Lupus,
March 1, 2001;
10(3):
154 - 161.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. John, K. Lietz, E. Burke, J. Ankersmit, D. Mancini, N. Suciu-Foca, N. Edwards, E. Rose, M. Oz, and S. Itescu
Intravenous Immunoglobulin Reduces Anti-HLA Alloreactivity and Shortens Waiting Time to Cardiac Transplantation in Highly Sensitized Left Ventricular Assist Device Recipients
Circulation,
November 9, 1999;
100
(2009):
II-229 - II-235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C A Slater, M H Liang, J W McCune, G M Christman, and M R Laufer
Preserving ovarian function in patients receiving cyclophosphamide
Lupus,
January 1, 1999;
8(1):
3 - 10.
[PDF]
|
|
|
|
|
|
|
I. Martin-Suarez, D. D'Cruz, M. Mansoor, A. P. Fernandes, M. A Khamashta, and G. R V Hughes
Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide
Ann Rheum Dis,
August 1, 1997;
56(8):
481 - 487.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Gavalchin and N.A. Staines
T and B cell recognition of idiotypes of anti-DNA autoantibodies
Lupus,
January 1, 1997;
6(3):
337 - 343.
[PDF]
|
|
|
|
|
|
|
W.M. Williams, N.A. Staines, S. Muller, and D.A. Isenberg
Human T cell responses to autoantibody variable region peptides
Lupus,
December 1, 1995;
4(6):
464 - 471.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Itescu, E. Burke, K. Lietz, R. John, D. Mancini, R. Michler, E. Rose, M. Oz, and N. Edwards
Intravenous Pulse Administration of Cyclophosphamide Is an Effective and Safe Treatment for Sensitized Cardiac Allograft Recipients
Circulation,
March 12, 2002;
105(10):
1214 - 1219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
